CL2018000223A1 - Combinación de antagonista de pd-1 con un inhibidor de egfr - Google Patents
Combinación de antagonista de pd-1 con un inhibidor de egfrInfo
- Publication number
- CL2018000223A1 CL2018000223A1 CL2018000223A CL2018000223A CL2018000223A1 CL 2018000223 A1 CL2018000223 A1 CL 2018000223A1 CL 2018000223 A CL2018000223 A CL 2018000223A CL 2018000223 A CL2018000223 A CL 2018000223A CL 2018000223 A1 CL2018000223 A1 CL 2018000223A1
- Authority
- CL
- Chile
- Prior art keywords
- combination
- antagonist
- egfr inhibitor
- medicinal product
- treatment
- Prior art date
Links
- 229940124060 PD-1 antagonist Drugs 0.000 title abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN ANTAGONISTA DE PD-1 Y UN INHIBIDOR DE EGFR. LA PRESENTE COMBINACIÓN SE PUEDE ADMINISTRAR EN FORMA INDEPENDIENTE O POR SEPARADO, EN UNA CANTIDAD QUE ES TERAPÉUTICAMENTE EFICAZ CONJUNTAMENTE PARA EL TRATAMIENTO DEL CÁNCER. LA INVENCIÓN TAMBIÉN PROPORCIONA EL USO DE DICHA COMBINACIÓN PARA LA FABRICACIÓN DE UN MEDICAMENTO, EL USO DE DICHA COMBINACIÓN COMO MEDICAMENTO; UN EQUIPO DE PARTES QUE COMPRENDE DICHA COMBINACIÓN; Y UN MÉTODO DE TRATAMIENTO DE DICHA COMBINACIÓN.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198390P | 2015-07-29 | 2015-07-29 | |
| US201662331371P | 2016-05-03 | 2016-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000223A1 true CL2018000223A1 (es) | 2018-07-13 |
Family
ID=56682137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000223A CL2018000223A1 (es) | 2015-07-29 | 2018-01-26 | Combinación de antagonista de pd-1 con un inhibidor de egfr |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180177872A1 (es) |
| EP (1) | EP3328407A1 (es) |
| JP (1) | JP2018523652A (es) |
| KR (1) | KR20180030911A (es) |
| CN (1) | CN108235685A (es) |
| AU (1) | AU2016298823A1 (es) |
| BR (1) | BR112018001640A2 (es) |
| CA (1) | CA2993908A1 (es) |
| CL (1) | CL2018000223A1 (es) |
| HK (1) | HK1247850A1 (es) |
| IL (1) | IL256775A (es) |
| MX (1) | MX2018001268A (es) |
| PH (1) | PH12018500097A1 (es) |
| RU (1) | RU2018105846A (es) |
| WO (1) | WO2017017624A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| RS59853B1 (sr) | 2014-03-14 | 2020-02-28 | Novartis Ag | Molekuli anti-lag-3 antitela i njihove upotrebe |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| WO2017087589A2 (en) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| EP3746119A4 (en) * | 2018-02-01 | 2021-11-10 | Merck Sharp & Dohme Corp. | METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| US20190380998A1 (en) | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| EP3806846A1 (en) | 2018-06-15 | 2021-04-21 | Board of Regents, The University of Texas System | Methods of treating and preventing breast cancer with s-equol |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| SG11202103812RA (en) * | 2018-10-17 | 2021-05-28 | Immunome Inc | Exosome-targeting bispecific antibodies |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| CR20210215A (es) | 2018-10-31 | 2021-06-17 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| KR102808642B1 (ko) | 2019-03-07 | 2025-05-14 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| SI4037708T1 (sl) | 2019-09-30 | 2025-01-31 | Gilead Sciences, Inc. | Cepiva proti hbv in postopki zdravljenja hbv |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| KR20240019330A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항체 약물 접합체의 조합 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1511900A (en) * | 1923-12-10 | 1924-10-14 | John A Mandis | Snap fastener |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| ES2639857T3 (es) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Anticuerpos monoclonales para el tratamiento del tumor |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| SMT202500126T1 (it) | 2008-12-09 | 2025-05-12 | Hoffmann La Roche | Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| JO3300B1 (ar) * | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| WO2015083059A1 (en) | 2013-12-02 | 2015-06-11 | Novartis Ag | Forms of the egfr inhibitor |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3389712B1 (en) * | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
-
2016
- 2016-07-27 MX MX2018001268A patent/MX2018001268A/es unknown
- 2016-07-27 EP EP16750496.8A patent/EP3328407A1/en not_active Withdrawn
- 2016-07-27 CN CN201680057132.5A patent/CN108235685A/zh active Pending
- 2016-07-27 RU RU2018105846A patent/RU2018105846A/ru not_active Application Discontinuation
- 2016-07-27 BR BR112018001640A patent/BR112018001640A2/pt not_active Application Discontinuation
- 2016-07-27 WO PCT/IB2016/054488 patent/WO2017017624A1/en not_active Ceased
- 2016-07-27 CA CA2993908A patent/CA2993908A1/en not_active Abandoned
- 2016-07-27 KR KR1020187005362A patent/KR20180030911A/ko not_active Withdrawn
- 2016-07-27 US US15/877,436 patent/US20180177872A1/en not_active Abandoned
- 2016-07-27 AU AU2016298823A patent/AU2016298823A1/en not_active Abandoned
- 2016-07-27 HK HK18107449.2A patent/HK1247850A1/zh unknown
- 2016-07-27 JP JP2018504285A patent/JP2018523652A/ja active Pending
-
2018
- 2018-01-07 IL IL256775A patent/IL256775A/en unknown
- 2018-01-11 PH PH12018500097A patent/PH12018500097A1/en unknown
- 2018-01-26 CL CL2018000223A patent/CL2018000223A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018001640A2 (pt) | 2018-09-18 |
| AU2016298823A1 (en) | 2018-02-08 |
| PH12018500097A1 (en) | 2018-07-23 |
| HK1247850A1 (zh) | 2018-10-05 |
| CA2993908A1 (en) | 2017-02-02 |
| RU2018105846A (ru) | 2019-08-28 |
| MX2018001268A (es) | 2018-07-06 |
| US20180177872A1 (en) | 2018-06-28 |
| JP2018523652A (ja) | 2018-08-23 |
| EP3328407A1 (en) | 2018-06-06 |
| IL256775A (en) | 2018-03-29 |
| KR20180030911A (ko) | 2018-03-26 |
| WO2017017624A1 (en) | 2017-02-02 |
| CN108235685A (zh) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
| CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
| ZA202308496B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| MX2017010773A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer. | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| MX2016010216A (es) | Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos. | |
| PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX391858B (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
| PE20141792A1 (es) | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2017003469A (es) | Inhibidores macrociclicos de cinasa rip2. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| MX394216B (es) | Abx196 para usarse en el tratamiento del cáncer de vejiga. | |
| ZA201606135B (en) | Pharmaceutical compositions of therapeutically active compounds |